Latest news with #Eikon
Time of India
7 days ago
- Business
- Time of India
Can rising EPS estimates restore investors confidence despite tariff uncertainties?
Mumbai: Investors may have a reason to cheer amid elevated uncertainties over the fallout of tariffs in the near term. Analysts have increased the earnings per share (EPS) estimates of most large companies following the March quarter, reversing two straight quarters of downgrades. Of the companies on the Nifty 500 index tracked by at least five analysts or more, 315 saw EPS upgrades in the fourth quarter compared with the December quarter, according to data from Eikon. EPS estimate upgrades signal improving earnings outlook, boosting investor confidence and often driving stock prices higher. "After two consecutive quarters of disappointing earnings, we've now seen some early rounds of earnings upgrades from analysts across selective companies following the fourth quarter numbers," said Aniruddha Sarkar, chief investment officer and portfolio manager at Quest Investment Advisors. "Government capex picking up sharply in the last four months is largely responsible for the same, along with a pickup in consumer spending." Analysts had moderated the earnings outlook in the previous two quarters after profits slowed to single digits amid concerns over an economic slowdown. The EPS growth of Nifty 50 was at 4.1% in the June quarter and 8.9% in the September quarter from the year-ago periods. In January-March, EPS grew at 10.9% from the same period a year ago. The EPS growth for FY25 was at 9% year-on-year. Live Events Agencies Slowing corporate earnings and the resultant downgrades by analysts were reasons for the sell-off in Indian equities between September-end and March, as investors found stock valuations rich in the face of the squeeze in profitability. Money managers expect further recovery in earnings in the quarters ahead. The Nifty's EPS is expected to grow at about 13% on a compounded basis between FY25 and FY27, up from 10.9% in the fourth quarter, supported by a lower base of FY25, accommodative monetary policy, and continued government spending , said Nikhil Rungta, co-chief investment officer - equity at LIC Mutual Fund. "Banks benefited from improved asset quality, while the auto sector saw steady domestic demand and successful new launches," he said. "Government-led capex supported infrastructure and real estate, and a rural demand revival boosted consumption." The pace of upgrades will be crucial for determining the direction of the market. "We believe the first quarter of FY26 could see some more modest upgrades but the pace of upgrades across the broader market could pick up from Q2 onwards as the low base of FY25 will come into play," said Sarkar.
Business Wire
29-05-2025
- Business
- Business Wire
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting
MILLBRAE, Calif. & CHICAGO--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate drug discovery, today announced that new data from its oncology programs will be presented in collaboration with independent investigators at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 – June 3, 2025, in Chicago, Illinois. Alongside these presentations, Eikon will also share additional milestone updates across its broad and diverse research and development pipeline. We are pleased to share these advances with the oncology community at ASCO as we work to deliver new medicines to address serious illnesses. Share 'We are encouraged by the progress we are seeing across our clinical-stage oncology programs, which reflect both the potential of these candidates and the capabilities of the fully integrated development organization that we are building at Eikon,' said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer of Eikon Therapeutics. 'Our team brings deep experience in advancing therapies through clinical studies and regulatory review, and we are pleased to see that capability reflected in the progress of our lead programs. At the same time, we continue to advance a pipeline of internally derived candidates, informed by the insights of our novel technology platform and Single Molecule Tracking (SMT) system. We look forward to positioning our results in the context of what has been achieved by the broader ASCO community.' ASCO 2025 Presentations The following posters will spotlight new first-in-human and combination data from Eikon's two most advanced clinical programs. EIK1001-006 (Abstract: TPS9604) Title: TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma Date and time: June 1, 2025, from 9:00 AM – 12:00 PM CDT Presenter: Jason J. Luke, M.D., UPMC, Hillman Cancer Center EIK1003-001 (Abstract: 3122) Title: Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors Date and time: June 2, 2025, from 1:30 PM – 4:30 PM CDT Presenter: Guru P. Sonpavde, M.D., AdventHealth Cancer Institute Recent Program Milestones In addition to its presentations at ASCO, Eikon will be discussing recent program milestones including: EIK1001-006 (TeLuRide-006, NCT06697301): The first patient has been enrolled in the TeLuRide-006 trial, which is investigating the potential role of EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 that has been observed to exhibit clinical activity as a monotherapy and in combination with anti-PD-(L)1 agents across multiple solid tumor types in Phase 1 trials, as an addition to standard of care pembrolizumab (KEYTRUDA ®) for the treatment of patients with advanced metastatic melanoma. TeLuRide-006 is a global, multicenter, randomized, double-blind, active comparator-controlled, adaptive Phase 2/3 trial to evaluate the safety and efficacy of EIK1001 and pembrolizumab versus placebo and pembrolizumab as first-line therapy in participants with advanced melanoma. The trial includes dose optimization and dose expansion parts. Eikon has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). Under the terms of the Agreement, Merck will provide pembrolizumab to Eikon. Eikon will be the sponsor of the Phase 2/3 clinical trial. EIK1001-005 (TeLuRide-005, NCT06246110): Enrollment continues as planned in this Phase 2 trial testing EIK1001 with pembrolizumab and chemotherapy in patients with squamous and nonsquamous non-small cell lung cancer. The trial's primary objective is to evaluate the safety and tolerability of EIK1001. Eikon also hopes to learn whether the immunomodulatory mechanism of EIK1001 might improve standard therapy in this hard-to-treat setting. EIK1003-001 (NCT06253130): Enrollment is proceeding in the trial of EIK1003, a highly selective PARP1 inhibitor, in adults with advanced solid tumors. Initial pharmacokinetic, safety, tolerability, and early efficacy findings from the monotherapy dose-escalation cohort will be reported in an ASCO 2025 poster (Abstract: 3122). EIK1004-001 (NCT06907043): The first patient has been dosed in a Phase 1/2 trial of EIK1004, a CNS-penetrant selective PARP1 inhibitor. This trial is assessing safety, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity in patients with advanced solid tumors, including those with brain metastases. 'The steady progress we are making as evidenced by the first safety and efficacy data from EIK1003, the initiation of our adaptive melanoma study with EIK1001, and the recent first-patient dosing of the CNS-penetrant selective PARP1 inhibitor EIK1004, underscores the momentum Eikon's clinical team is building across our oncology portfolio,' said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon Therapeutics. 'Their deep experience in oncology is translating into real world progress, and we are pleased to share these advances with the oncology community at ASCO as we work to deliver new medicines to address serious illnesses.' Eikon at AACR 2025 The Eikon Therapeutics team also recently presented program data at the 2025 American Association for Cancer Research (AACR) conference. These presentations included: EIK1004-001 (Abstract#5719): Identification of EIK1004: A CNS-penetrant, potent and selective PARP1 inhibitor poised for testing in patients with HRD mutant tumors. The poster presented data on methodologies to optimize early lead PARP1 inhibitors with novel structures for selectivity and CNS penetration leading to discovery of EIK1004. EIK1003-001 (Abstract # CT197): A first-in-human, Phase 1/2 dose escalation, dose-optimization, and dose-expansion trial of PARP1-selective inhibitor EIK1003 in patients with advanced solid tumors. The Eikon team will also welcome attendees at ASCO Booth #14143 to discuss these and its other pipeline programs. About Eikon Therapeutics Eikon Therapeutics is dedicated to advancing breakthrough therapies through the purposeful integration of science and engineering. Our research tools, including our proprietary SMT system, leverage Nobel Prize-winning super-resolution microscopy, bespoke automation, advanced data science, and software engineering to visualize and measure the real-time movement of proteins in living cells, with the goal of developing important innovative medicines to address serious unmet medical needs. Eikon operates from its facilities in California, New Jersey, and New York, and can be found online at or LinkedIn.
San Francisco Chronicle
24-05-2025
- Business
- San Francisco Chronicle
Bay Area biotech company cuts 55 jobs, blames Trump-era funding reductions
A Bay Area biotech company has laid off 55 employees, citing funding cuts linked to policies from the Trump administration — just three months after raising nearly $351 million in funding. In a regulatory notice filed Wednesday, Eikon Therapeutics, based in Millbrae, confirmed that the layoffs would impact nearly 15% of its workforce. The cuts are set to take effect in July. Eikon, known for its work in developing cancer treatments, explained that the job cuts were driven by a combination of government funding reductions and the cooling biotech sector. 'To be clear, these decisions were precipitated by external forces,' the company said Thursday in a LinkedIn post. 'For example, government funding cuts have constrained the budget of academic institutions, necessitating that we pause development of our advanced instruments intended for external researchers.' Founded in 2021 to advance drug discovery through live-cell super-resolution microscopy, Eikon quickly attracted significant investment. The company raised a $517 million Series B round in 2022, followed by a $350.7 million Series D round in February. 'The market for these instruments has clearly evaporated,' the company's LinkedIn post continued. 'Similarly, with reduced investment in the global technology sector, prudence demands that Eikon sharpen its focus and generate efficiencies in our operations.'
Yahoo
01-04-2025
- Business
- Yahoo
Czech manufacturing downturn slows in March, PMI shows
PRAGUE (Reuters) - The contraction in Czech manufacturing eased in March, creeping closer to levels showing stabilisation as falls in output and orders slowed, the S&P Global Purchasing Managers' Index (PMI) showed on Tuesday. Headline PMI rose to 48.3 in March from 47.7 in February, staying below the 50 mark that divides expansion from contraction. The reading was mostly in line with a Reuters poll forecast of 48.5. The rate of decline in manufacturing has eased during the first quarter and was the weakest since the contraction started in June 2022. Among components, the fall in output was also the smallest in the cycle, helped by a softer reduction in new orders. Some firms saw demand conditions recovering, the survey said. Costs, though, rose in the month, largely due to materials prices, firms said. Some firms raised their selling prices for the first time since last year, according to the survey. Month/Year 03/25 02/25 03/24 Purchasing Managers' Index 48.3 47.7 46.2 Output 49.5 49.1 46.0 ** To monitor in real-time Czech economic data releases in the Eikon app and view historical data click: Sign in to access your portfolio
Reuters
01-04-2025
- Business
- Reuters
Czech manufacturing downturn slows in March, PMI shows
PRAGUE, April 1 (Reuters) - The contraction in Czech manufacturing eased in March, creeping closer to levels showing stabilisation as falls in output and orders slowed, the S&P Global Purchasing Managers' Index (PMI) showed on Tuesday. Headline PMI rose to 48.3 in March from 47.7 in February, staying below the 50 mark that divides expansion from contraction. The reading was mostly in line with a Reuters poll forecast of 48.5. The rate of decline in manufacturing has eased during the first quarter and was the weakest since the contraction started in June 2022. Among components, the fall in output was also the smallest in the cycle, helped by a softer reduction in new orders. Some firms saw demand conditions recovering, the survey said. Costs, though, rose in the month, largely due to materials prices, firms said. Some firms raised their selling prices for the first time since last year, according to the survey. ** To monitor in real-time Czech economic data releases in the Eikon app and view historical data click:
